The anti-inflammatory drugs market size has grown rapidly in recent years. It will grow from $136.86 billion in 2024 to $152.08 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. Growth during the historic period can be attributed to several key factors, including an aging population, the increasing prevalence of chronic inflammatory diseases, greater over-the-counter availability of medications, rising awareness of pain management, and the expansion of healthcare infrastructure.
The anti-inflammatory drugs market size is expected to see rapid growth in the next few years. It will grow to $228.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. Growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, increasing demand for personalized medicine, a growing geriatric population, supportive government initiatives, and a rising preference for topical and targeted therapies. Key trends anticipated during this period include innovations in biologic drugs, a shift toward biologics and biosimilars, the rise of telemedicine-based prescriptions, the integration of artificial intelligence in drug discovery, ongoing research and development of novel anti-inflammatory mechanisms, and advancements in targeted anti-inflammatory therapies.
The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory drugs market in the coming years. Arthritis is characterized by inflammation in one or more joints, leading to pain, swelling, and stiffness that often worsens with age. The growing incidence of arthritis is largely attributed to aging populations, as the natural wear and tear on joints over time raises the risk of developing the condition. Anti-inflammatory drugs play a key role in managing arthritis by reducing joint inflammation and pain, helping patients maintain mobility, perform daily activities more comfortably, and improve their overall quality of life. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in 2022, 17.6% of individuals aged 16 and above had a long-term musculoskeletal (MSK) condition - such as arthritis or persistent joint or back issues - an increase from 17% in 2021. Thus, the rising prevalence of arthritis is contributing significantly to the growth of the anti-inflammatory drugs market.
Leading companies in the anti-inflammatory drugs market are focusing on developing innovative formulations, such as topical solutions, to improve targeted drug delivery and enhance patient compliance. A topical solution is a liquid form of medication applied directly to the skin or affected area, allowing the active ingredients to act locally at the site of inflammation while minimizing systemic side effects. For example, in December 2022, Lupin Limited, an India-based pharmaceutical company, launched the authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution, 2% w/w) from Horizon Pharma Therapeutics in the United States. This move aimed to expand Lupin’s U.S. generics portfolio and improve access to affordable anti-inflammatory treatments. The drug, a nonsteroidal anti-inflammatory agent, is used to relieve pain caused by osteoarthritis of the knee, offering localized relief through topical application and reducing the systemic risks associated with oral NSAIDs.
In March 2022, Pfizer, a U.S.-based pharmaceutical company, acquired Arena Pharmaceuticals for approximately $6.7 billion. This acquisition was intended to strengthen Pfizer’s pipeline of potential therapies targeting immuno-inflammatory diseases, with a focus on areas such as gastroenterology, dermatology, and cardiology. Arena Pharmaceuticals, also based in the U.S., is a clinical-stage company dedicated to developing innovative treatments for a range of immuno-inflammatory conditions.
Major players in the anti-inflammatory drugs market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Cadila Pharmaceuticals, Samsung Bioepis, Lupin Limited.
North America was the largest region in the anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anti-inflammatory drugs are a category of medications designed to alleviate inflammation, pain, fever, and swelling by disrupting the body’s natural inflammatory processes. They function by blocking the activity or production of chemical messengers like prostaglandins, leukotrienes, and cytokines, which play key roles in initiating and maintaining inflammation.
The primary classes of anti-inflammatory drugs include steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics and biosimilars, among others. Steroids, which imitate natural hormones, are commonly used to manage conditions such as asthma, arthritis, and allergies. These medications can be administered in various forms, including parenteral, oral, topical, and inhalation routes. They are employed in the treatment of multiple conditions, including autoimmune and respiratory diseases. Anti-inflammatory drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The anti-inflammatory drugs market research report is one of a series of new reports that provides anti-inflammatory drugs market statistics, including anti-inflammatory drugs industry global market size, regional shares, competitors with the anti-inflammatory drugs market share, anti-inflammatory drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-inflammatory drugs industry. This anti-inflammatory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-inflammatory drugs market consists of sales of immunosuppressants, COX-2 inhibitors, interleukin inhibitors, and TNF-alpha inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The anti-inflammatory drugs market size is expected to see rapid growth in the next few years. It will grow to $228.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. Growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, increasing demand for personalized medicine, a growing geriatric population, supportive government initiatives, and a rising preference for topical and targeted therapies. Key trends anticipated during this period include innovations in biologic drugs, a shift toward biologics and biosimilars, the rise of telemedicine-based prescriptions, the integration of artificial intelligence in drug discovery, ongoing research and development of novel anti-inflammatory mechanisms, and advancements in targeted anti-inflammatory therapies.
The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory drugs market in the coming years. Arthritis is characterized by inflammation in one or more joints, leading to pain, swelling, and stiffness that often worsens with age. The growing incidence of arthritis is largely attributed to aging populations, as the natural wear and tear on joints over time raises the risk of developing the condition. Anti-inflammatory drugs play a key role in managing arthritis by reducing joint inflammation and pain, helping patients maintain mobility, perform daily activities more comfortably, and improve their overall quality of life. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in 2022, 17.6% of individuals aged 16 and above had a long-term musculoskeletal (MSK) condition - such as arthritis or persistent joint or back issues - an increase from 17% in 2021. Thus, the rising prevalence of arthritis is contributing significantly to the growth of the anti-inflammatory drugs market.
Leading companies in the anti-inflammatory drugs market are focusing on developing innovative formulations, such as topical solutions, to improve targeted drug delivery and enhance patient compliance. A topical solution is a liquid form of medication applied directly to the skin or affected area, allowing the active ingredients to act locally at the site of inflammation while minimizing systemic side effects. For example, in December 2022, Lupin Limited, an India-based pharmaceutical company, launched the authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution, 2% w/w) from Horizon Pharma Therapeutics in the United States. This move aimed to expand Lupin’s U.S. generics portfolio and improve access to affordable anti-inflammatory treatments. The drug, a nonsteroidal anti-inflammatory agent, is used to relieve pain caused by osteoarthritis of the knee, offering localized relief through topical application and reducing the systemic risks associated with oral NSAIDs.
In March 2022, Pfizer, a U.S.-based pharmaceutical company, acquired Arena Pharmaceuticals for approximately $6.7 billion. This acquisition was intended to strengthen Pfizer’s pipeline of potential therapies targeting immuno-inflammatory diseases, with a focus on areas such as gastroenterology, dermatology, and cardiology. Arena Pharmaceuticals, also based in the U.S., is a clinical-stage company dedicated to developing innovative treatments for a range of immuno-inflammatory conditions.
Major players in the anti-inflammatory drugs market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Cadila Pharmaceuticals, Samsung Bioepis, Lupin Limited.
North America was the largest region in the anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Anti-inflammatory drugs are a category of medications designed to alleviate inflammation, pain, fever, and swelling by disrupting the body’s natural inflammatory processes. They function by blocking the activity or production of chemical messengers like prostaglandins, leukotrienes, and cytokines, which play key roles in initiating and maintaining inflammation.
The primary classes of anti-inflammatory drugs include steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics and biosimilars, among others. Steroids, which imitate natural hormones, are commonly used to manage conditions such as asthma, arthritis, and allergies. These medications can be administered in various forms, including parenteral, oral, topical, and inhalation routes. They are employed in the treatment of multiple conditions, including autoimmune and respiratory diseases. Anti-inflammatory drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The anti-inflammatory drugs market research report is one of a series of new reports that provides anti-inflammatory drugs market statistics, including anti-inflammatory drugs industry global market size, regional shares, competitors with the anti-inflammatory drugs market share, anti-inflammatory drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-inflammatory drugs industry. This anti-inflammatory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-inflammatory drugs market consists of sales of immunosuppressants, COX-2 inhibitors, interleukin inhibitors, and TNF-alpha inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Anti-Inflammatory Drugs Market Characteristics3. Anti-Inflammatory Drugs Market Trends And Strategies4. Anti-Inflammatory Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Anti-Inflammatory Drugs Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Anti-Inflammatory Drugs Market34. Recent Developments In The Anti-Inflammatory Drugs Market
5. Global Anti-Inflammatory Drugs Growth Analysis And Strategic Analysis Framework
6. Anti-Inflammatory Drugs Market Segmentation
7. Anti-Inflammatory Drugs Market Regional And Country Analysis
8. Asia-Pacific Anti-Inflammatory Drugs Market
9. China Anti-Inflammatory Drugs Market
10. India Anti-Inflammatory Drugs Market
11. Japan Anti-Inflammatory Drugs Market
12. Australia Anti-Inflammatory Drugs Market
13. Indonesia Anti-Inflammatory Drugs Market
14. South Korea Anti-Inflammatory Drugs Market
15. Western Europe Anti-Inflammatory Drugs Market
16. UK Anti-Inflammatory Drugs Market
17. Germany Anti-Inflammatory Drugs Market
18. France Anti-Inflammatory Drugs Market
19. Italy Anti-Inflammatory Drugs Market
20. Spain Anti-Inflammatory Drugs Market
21. Eastern Europe Anti-Inflammatory Drugs Market
22. Russia Anti-Inflammatory Drugs Market
23. North America Anti-Inflammatory Drugs Market
24. USA Anti-Inflammatory Drugs Market
25. Canada Anti-Inflammatory Drugs Market
26. South America Anti-Inflammatory Drugs Market
27. Brazil Anti-Inflammatory Drugs Market
28. Middle East Anti-Inflammatory Drugs Market
29. Africa Anti-Inflammatory Drugs Market
30. Anti-Inflammatory Drugs Market Competitive Landscape And Company Profiles
31. Anti-Inflammatory Drugs Market Other Major And Innovative Companies
35. Anti-Inflammatory Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Anti-Inflammatory Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on anti-inflammatory drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anti-inflammatory drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-inflammatory drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Steroids; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Biologics And Biosimilars; Other Drug Classes2) By Route of Administration: Parenteral; Oral; Topical; Inhalation
3) By Applications: Autoimmune Diseases; Respiratory Diseases; Other Diseases
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Steroids: Corticosteroids; Mineralocorticoids2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Non-Selective Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Selective Cyclooxygenase-2 (COX-2) Inhibitors
3) By Biologics And Biosimilars: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin (IL) Inhibitors; Janus Kinase (JAK) Inhibitors; Other Biologics And Biosimilars
4) By Other Drug Classes: Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Immunosuppressants; Antihistamines
Key Companies Profiled: Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Gilead Sciences Inc.
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Biogen Inc.
- Vertex Pharmaceuticals Inc.
- UCB S.A.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories
- Cipla Limited
- Cadila Pharmaceuticals
- Samsung Bioepis
- Lupin Limited